Wersebe Annika, Wiskirchen Jakub, Decker Udo, Schick Fritz, Dietz Klaus, Müller-Schimpfle Markus, Claussen Claus D, Pereira Philippe L
Department of Diagnostic Radiology, University Hospital Tübingen, Germany.
Invest Radiol. 2006 Mar;41(3):264-71. doi: 10.1097/01.rli.0000188359.72928.0f.
We sought to compare signal changes using Ferucarbotran and gadobenate dimeglumine (Gd-BOPTA) in dynamic 3D T1-weighted (T1w) GRE imaging of the liver.
Thirty patients were prospectively included in the study. All patients underwent 2 high-field magnetic resonance (MR) examinations: first with Gd-BOPTA (Gd) and then after a mean interval of 4 days with ferucarbotran (Feru). Dynamic MRI was obtained with a 3D T1w GRE sequence (TR 6.33, TE 2.31, flip angle 20 degrees ). Contrast enhanced scans were assessed before intravenous injection of the contrast agent (precontrast), and postcontrast during the arterial phase (30 seconds), portal venous phase (60 seconds), and equilibrium phase (120 seconds). The signal intensities (SIs) of liver, spleen, aorta, and portal vein were defined by region of interest measurements. Signal intensity changes (SICs) and percentage signal intensity change (PSIC) were calculated using the formulas SIC=(SI pre - SI post)/SI pre and PSIC=SIC x 100%.
Positive signal enhancement was observed after intravenous injection of Feru during all dynamic measurements, whereas the mean SI values were lower compared with Gd. During the portal venous phase the mean SI of Gd was up to a factor of 2.1 higher (portal vein). The widest difference of SIC was observed during the equilibrium phase for liver parenchyma (Gd, 1.03; Feru, 0.24). The dynamic signal courses were similar for liver, portal vein and aorta. Different signal courses were obtained for the spleen.
Feru-enhanced T1w dynamic images demonstrated significant signal increases for liver, vessels, and spleen but overall lower signal intensities than Gd-BOPTA. The dynamic signal courses of ferucarbotran were similar to that of Gd-BOPTA during ll perfusion phases except in the spleen. Thus, it may be possible to detect typical enhancement pattern of focal liver lesions with Feru-enhanced dynamic T1w MRI.
我们试图比较在肝脏动态三维T1加权（T1w）梯度回波（GRE）成像中使用羧基麦芽糖铁和钆贝葡胺（Gd-BOPTA）后的信号变化。
前瞻性纳入30例患者进行本研究。所有患者均接受2次高场磁共振（MR）检查：第一次使用Gd-BOPTA（Gd），然后平均间隔4天后使用羧基麦芽糖铁（Feru）。采用三维T1w GRE序列（TR 6.33，TE 2.31，翻转角20度）获得动态MRI图像。在静脉注射造影剂前（造影前）以及动脉期（30秒）、门静脉期（60秒）和平衡期（120秒）造影后评估对比增强扫描。通过感兴趣区测量来定义肝脏、脾脏、主动脉和门静脉的信号强度（SIs）。使用公式SIC =（SI前 - SI后）/ SI前和PSIC = SIC×100%计算信号强度变化（SICs）和信号强度变化百分比（PSIC）。
在所有动态测量中，静脉注射Feru后均观察到阳性信号增强，但其平均SI值低于Gd。在门静脉期，Gd的平均SI值高出2.1倍（门静脉）。肝实质在平衡期观察到SIC的最大差异（Gd，1.03；Feru，0.24）。肝脏、门静脉和主动脉的动态信号过程相似。脾脏获得了不同的信号过程。
Feru增强的T1w动态图像显示肝脏、血管和脾脏的信号显著增加，但总体信号强度低于Gd-BOPTA。除脾脏外，羧基麦芽糖铁在所有灌注期的动态信号过程与Gd-BOPTA相似。因此，使用Feru增强的动态T1w MRI有可能检测到肝脏局灶性病变的典型增强模式。
